Cover Image

Pheochromocytoma: An overlooked reversible cause of heart failure with reduced ejection fraction

Saved in:

Bibliographic Details
Main Authors:	Ali Çoner (Author), Ali Gökhan Özyıldız (Author)
Format:	Book
Published:	KARE Publishing, 2021-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Comparison of clinical features and conventional echocardiographic characteristics of patients with heart failure with mid-range ejection fraction with and without interatrial block
by: Ali Çoner
Published: (2021)

New to paradigm for the treatment of heart failure with reduced ejection fraction?
by: Delfín Rodríguez Leyva
Published: (2015)

Outcome of angiotensin receptor-neprilysin inhibitor on anxiety and depression in heart failure with reduced ejection fraction vs. heart failure with preserved ejection fraction
by: Jahanzeb Malik, et al.
Published: (2021)

Angiotensin receptor blocker-neprilysin inhibitor for heart failure with reduced ejection fraction
by: Dima Nasrallah, et al.
Published: (2024)

Role of ARNI upgraded in treatment of heart failure with reduced ejection fraction
by: Swetha Amaresh Biradar
Published: (2021)

How to treat cardiac dyssynchrony in heart failure with reduced ejection fraction
by: Bogdan Stefan, et al.
Published: (2024)

Hemorheological Alterations in Patients with Heart Failure with Reduced Ejection Fraction Treated by Resveratrol
by: Roland Gal, et al.
Published: (2020)

Dapagliflozin versus sacubitril-valsartan for heart failure with mildly reduced or preserved ejection fraction
by: Ronen Arbel, et al.
Published: (2024)

Vericiguat in Heart Failure with a Reduced Ejection Fraction: Patient Selection and Special Considerations
by: Kassis-George H, et al.
Published: (2022)

ALGORITHM FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEART FAILURE WITH REDUCED LEFT VENTRICULAR EJECTION FRACTION
by: E. V. Reznik, et al.
Published: (2018)

Lymphocytopenia is associated with poor NYHA functional class in chronic heart failure patients with reduced ejection fraction
by: Hasan Yucel, et al.
Published: (2015)

Prognostic of NT-proBNP in heart failure patients with preserved, mid and reduced ejection fraction
by: Reynie Leonel Reinoso Gonella, et al.
Published: (2021)

Heart Failure with Preserved and Reduced Ejection Fraction in Hemodialysis Patients: Prevalence, Disease Prediction and Prognosis
by: Marlies Antlanger, et al.
Published: (2017)

Safety of midodrine in patients with heart failure with reduced ejection fraction: a retrospective cohort study
by: Ming-Ju Wu, et al.
Published: (2024)

Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China
by: Yi Tang, et al.
Published: (2022)

New possibilities in pharmacotherapy for the heart failure with reduced ejection fraction treatment in patients with recent deterioration
by: I. V. Gribkova
Published: (2024)

Cost-Effectiveness Analysis of the Adjunctive Therapy of Ivabradine for the Treatment of Heart Failure with Reduced Ejection Fraction
by: Krittayaphong R, et al.
Published: (2019)

Plasma digoxin levels and ejection fraction in pediatric heart failure
by: Nafrialdi Nafrialdi, et al.
Published: (2016)

Pediatric heart failure with preserved ejection fraction, a review
by: Sophie Quennelle, et al.
Published: (2023)

Unveiling the impact of an Indian-specific heart failure checklist on heart failure with reduced ejection fraction management in the South Indian population
by: Anu Philip, et al.
Published: (2024)

Wild type transthyretin cardiac amiloidozis as a rare and overlooked underlying etiology in a patient with heart failure with preserved ejection fraction and left ventricular hypertrophy
by: Selda Murat, et al.
Published: (2021)

Cost-utility analysis of add-on vericiguat for the treatment of chronic heart failure with reduced ejection fraction in China
by: Lu Wang, et al.
Published: (2024)

Web-Based Dynamic Nomogram for Predicting Risk of Mortality in Heart Failure with Mildly Reduced Ejection Fraction
by: Guo W, et al.
Published: (2024)

Safety of dapagliflozin initiation in acute decompensated heart failure patients with reduced left ventricular ejection fraction
by: Anastasiya E. Poskakalova, et al.
Published: (2023)

Duration of Heart Failure With Reduced Ejection Fraction Associated With Electrocardiographic Outcomes Before and After Sacubitril/Valsartan
by: Po-Lin Lin MD, et al.
Published: (2022)

Delaminating Intramyocardial Hematoma in Patients with Heart Failure with Reduced Ejection Fraction: а Series of Clinical Cases
by: A. F. Safarova, et al.
Published: (2023)

Health-related quality of life among congestive heart failure patients with preserved and reduced ejection fraction
by: Hudiyawati Dian, et al.
Published: (2024)

Management of a Patient with Severe Hypotension and Advanced Heart Failure with Reduced Left Ventricular Ejection Fraction
by: M. S. Bychkova, et al.
Published: (2022)

Evaluation of aldosterone antagonist utilization in heart failure with reduced and preserved ejection fraction at an academic medical center
by: Bradley D, et al.
Published: (2019)

The Prognostic Impact of Circulating Regulatory T Lymphocytes on Mortality in Patients with Ischemic Heart Failure with Reduced Ejection Fraction
by: Andreas Hammer, et al.
Published: (2020)

Emerging concepts in heart failure management and treatment: focus on current guideline-directed medical therapy for heart failure with reduced ejection fraction
by: Oscar Eduardo Ospina González, et al.
Published: (2023)

Cardiac Amyloidosis - An Underdiagnosed Cause of Heart Failure with Preserved Ejection Fraction - Updated Diagnosis and Treatment Options
by: Roxana Cristina RIMBAS, et al.
Published: (2021)

Heart Failure with Perserved Ejection Fraction Current Diagnostic and Therapeutic Approaches
by: A. A. Shchendrygina, et al.
Published: (2021)

NADPH Oxidases in Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction
by: James P. Teuber, et al.
Published: (2022)

Pediatric heart failure classification based on left ventricular ejection fraction
by: Shan Huang, et al.
Published: (2023)

Heart failure with preserved ejection fraction (HFpEF): Implications for the anesthesiologists
by: Ajmer Singh, et al.
Published: (2018)

Healthcare resource utilization and costs among patients with heart failure with preserved, mildly reduced, and reduced ejection fraction in Spain
by: Carlos Escobar, et al.
Published: (2022)

Prognostic value of depression, anxiety disorders and inflammatory markers in patients with reduced and mildly reduced ejection fraction heart failure
by: Emine Gazi, et al.
Published: (2022)

Optimization of GDMT for patients with heart failure and reduced ejection fraction: can physiological and biological barriers explain the gaps in adherence to heart failure guidelines?
by: Marilyne Jarjour, et al.
Published: (2023)

Predictors of Coronary Artery Disease in Heart Failure with Reduced Ejection Fraction at the Aga Khan University Hospital in Nairobi
by: Redemptar Kimeu, et al.
Published: (2023)